ArticleOpen forum infectious diseases2022
Daptomycin-Resistant
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Non-susceptibility ofMicrobiology spectrum · 2026Article
- Understanding Daptomycin Resistance Mechanisms and Treatment Challenges inAntibiotics (Basel, Switzerland) · 2026Article
- Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis.BMC infectious diseases · 2025Article
- Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin.Nature communications · 2025Article
- Asymptomatic faecal carriage of vancomycin-resistant Enterococci among inpatients and outpatients in a Kenyan hospital: a cross-sectional study.Antimicrobial resistance and infection control · 2025Article
- Rates of Acute Kidney Injury Utilizing Area Under the Concentration-Time Curve Versus Trough-Based Vancomycin Dosing Strategies in Patients With Obesity.Open forum infectious diseases · 2025Article
- Comparative Efficacy of High-Dose Daptomycin Monotherapy versus Combination Therapy for Daptomycin-ResistantInfection and drug resistance · 2025Article
- Management of vancomycin-resistant Enterococci and daptomycin-resistant Enterococci infections in liver transplant recipients in a single academic center.Transplant infectious disease : an official journal of the Transplantation Society · 2024Article
- Article
- ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.Nature reviews. Microbiology · 2024Review
- The Impact ofPathogens (Basel, Switzerland) · 2024Review
- New Approaches to Manage Infections in Transplant Recipients: Report From the 2023 GTI (Infection and Transplantation Group) Annual Meeting.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Predicting VRE Infection After Liver Transplantation With a Time-Updated Colonization Score.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRisk factors for acquisition of vancomycin-resistant
methodsWe conducted a retrospective multicenter cohort study comparing liver transplant recipients with either VRE or DRE bacteremia. The primary outcome was death within 1 year of transplantation. Multivariable logistic regression analyses were performed to calculate adjusted odds ratios for outcomes of interest.
resultsWe identified 139 cases of
conclusionsIn this multicenter study of LT recipients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.